|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, a possible interaction between the NAT2 slow acetylator genotype and smoking status was suggested.
|
12622714 |
2003 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
For the NAT2 slow acetylator genotype, the NAT2*5/*7 diplotype was found to have a 7-fold increased risk of bladder (OR=7.14; 95% CI: 1.30-51.41).
|
19380028 |
2009 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The results of this study support an association between the NAT2 slow acetylator genotype and FPD in our population.
|
10634239 |
2000 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The NAT2 slow acetylator genotype was significantly associated with risk of GBC (OR 3.4, 95% CI =1.9-5.7 p = 0.000007).
|
17224641 |
2007 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Smoking and salted tea consumption were independent risk factors, but they did not show any interaction with NAT2 slow acetylator genotypes.
|
19766908 |
2009 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The risks of hepatic injury were higher after anti-tuberculosis therapy in patients carrying the NAT2 slow acetylator, CYP2E1 -1259G>C, -1019C>T wild-type, and GSTM1 null genotype.
|
25501156 |
2014 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Bus drivers with the GSTM1 null and slow acetylator NAT2 genotype had an increased frequency of cells with chromosomal aberrations.
|
10207633 |
1999 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We inferred the NAT1 rapid and slow acetylator and the NAT2 rapid, intermediate or slow acetylator phenotype, based on published functional data on the respective genotypes.
|
25689677 |
2016 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Many patients were found to have the slow acetylator genotype of N-acetyltransferase (NAT) 2, suggesting that the NAT2 genotype is a susceptibility factor.
|
14605423 |
2003 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that SULT1A1 *1/*1 and NAT2 slow acetylator genotypes might modulate the effect of carcinogenic arylamines contained in tobacco smoke, and that the modulation of NAT2 intermediate and slow acetylator genotype has a tendency to present a higher risk for highly differentiated tumors among heavy-smokers.
|
14648207 |
2004 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The relationship between the slow acetylator NAT2 genotype and HCC risk is more pronounced in patients lacking serum HBV and HCV markers.
|
9014199 |
1996 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Overall, we found significant association between slow acetylator genotype of NAT2 and ATDH (OR = 3.10, 95% CI: 2.47-3.88, P < 10(-5)).
|
23277397 |
2013 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Therefore, the NAT2 polymorphism was believed to be associated with increased risk of CHD, with the NAT2 slow acetylator genotype serving as a risk factor for severe CHD in a Chinese population.
|
26985933 |
2016 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The joint effects in the highest risk category (NAT2 slow acetylator, NAT1 fast acetylator, and current or ever cigarette smoking) as compared with the reference category (NAT2 fast acetylator, NAT1 slow acetylator, and never smoking) were associated with an odds ratio of 2.73 (95% CI: 1.70, 4.31).
|
17675654 |
2007 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, compared to individuals with rapid NAT2 genotype, women with the very slow acetylator genotype (NAT2*5), who smoked for 20 years showed an increased breast cancer risk (OR=2.29; 95% CI 1.06-4.95).
|
12835615 |
2003 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
NAT2 genotype was determined using allele-specific polymerase chain reaction amplification to detect slow acetylator mutations.
|
10898115 |
2000 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, individuals possessing combined genotypes of N-acetyltransferase 2 (NAT2) rapid acetylator, GSTP1 mutant and both GSTT1(-) and GSTM1(-) have a remarkably higher lung cancer risk than those carrying combined NAT2 slow acetylator genotype, GSTP1 wild genotype and both GSTT1(+) and GSTM1(+) genotypes.
|
16788248 |
2006 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The risk of anti-TB DIH was significantly higher in slow acetylator (SA) than in intermediate and rapid acetylator of NAT2 genotypes (odds ratio: 2.3, P = 0.01).
|
23875638 |
2013 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Among the low-penetrant genes, the variants within the genes encoding metabolic enzymes have been consistently associated with susceptibility to bladder cancer and the evidence is compelling for NAT2 slow acetylator and GSTM1 null genotypes.
|
21738036 |
2011 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The slow acetylator genotype for N-acetyltransferase 2 was more common in the familial PD group (69%) than in all controls (37%).
|
9343502 |
1997 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The present meta-analysis indicates that the CYP2E1 c1/c1 genotype may be a risk factor for ATDH, and the concomitant presence of the slow acetylator NAT2 genotype may further increase this risk.
|
24607341 |
2014 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
There is a significant association between PD and the slow acetylator genotype for N-acetyltransferase 2 in Hong Kong Chinese.
|
12654968 |
2003 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
After adjusting for potential confounders, as well as for other GST gene variants, lung adduct levels significantly increased by 150.3% [95% confidence interval (95% CI), 35.4-362.6%] for the GSTM1 null and by 73.9% (95% CI, -3.2% to 212.4%) for the NAT2 slow acetylator genotype, respectively.
|
20501762 |
2010 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Comparison of the genotype frequencies in HIV-positive and -negative patients showed that the NAT2 slow acetylator genotype frequency in the HIV-positive patients (74%) was significantly (Pc = 0.0003, OR = 2.3) higher than in control subjects (56%).
|
11186133 |
2000 |
|
Slow acetylator due to N-acetyltransferase enzyme variant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Particular consideration is given to associations between antituberculosis drug-related liver injury and the "slow acetylator" genotype for N-acetyltransferase 2, amoxicillin/clavulanate-related liver injury, and the human leukocyte antigen (HLA) class II DRB1*1501 allele and flucloxacillin-related injury and the HLA class I B*5701 allele.
|
19826974 |
2009 |